Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics (FLGT) to $16 from $22 following quarterly results. The firm keeps a Neutral rating on the shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT: